Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

Fortress Biotech, Helocyte have announced the dosing of the first subject in the trial of Triplex for individuals who are ...

Fortress Biotech (NASDAQ:FBIO)'s Chairman and CEO, Dr. Lindsay (NYSE:LNN) A. Rosenwald, expressed optimism about the vaccine's role in preventing and treating CMV in the future. While analysts ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

How do researchers know the effectiveness of... There are currently at least six COVID-19 vaccines in phase 3 clinical trials – the final phase of testing. These trials all aim to compare the ...

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

Saint-Herblain (France), January 22, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Fortress Biotech (FBIO) and its majority-owned subsidiary, Helocyte, announced that the first patient was dosed in a ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.